Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

GSK, CureVac team up to develop vaccine against COVID-19 variants

CoronavirusFeb 03, 2021 09:25
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. FILE PHOTO: Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility 2/2

By Ludwig Burger

FRANKFURT (Reuters) - Britain's GlaxoSmithKline and German biotech firm CureVac have teamed up in a 150 million euro ($180 million) deal to develop a COVID-19 vaccine from next year that could target several variants with one shot.

New, more contagious mutations of COVID-19 have emerged in Britain, South Africa and Brazil and while existing vaccines appear to offer some protection against them, there are fears further changes in the virus could evade current shots.

For GSK, the world's largest vaccine maker by sales, the deal marks a fresh attempt to play a major role in fighting the pandemic after a COVID-19 alliance with Sanofi (PA:SASY) ran into delays and a collaboration with China's Clover Biopharmaceuticals was ended.

GSK, which acquired a 10% stake in CureVac last year, will also support the production of up to 100 million doses of CureVac's first generation COVID-19 vaccine candidate in 2021, the companies said in a joint statement on Wednesday.

A CureVac spokesman said that would firm up group's target to produce up to 300 million doses this year.

Having started mass testing of its vaccine candidate in Europe and Latin America in December, CureVac expects an initial readout from that study in March or April.

CureVac is also collaborating with Bayer (DE:BAYGN) to speed up development and production of that vaccine.

The German biotech firm is banking on messenger RNA, a cutting-edge genetic technology that has allowed rivals BioNTech and Moderna (NASDAQ:MRNA) to lead the COVID-19 vaccine development race.

GSK, while having done early research into mRNA vaccines against various diseases, has so far focused its pandemic response on a more traditional vaccine approach.

It has been providing adjuvants, which are efficacy boosting ingredients, to developers of protein-based vaccines.

GSK, which is scheduled to release 2020 results at 1200 GMT, will pay CureVac 75 million euros upfront, adding another 75 million if certain development milestones are achieved.

($1 = 0.8308 euros)

GSK, CureVac team up to develop vaccine against COVID-19 variants
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (3)
mushaf munas
mushaf munas Feb 03, 2021 13:52
Saved. See Saved Items.
This comment has already been saved in your Saved Items
GSK is out if Market. Not updating with new science. Tool little too late. Moderna & pfizer already leading and vaccinating the people.
Karsten Böhm
Karsten Böhm Feb 03, 2021 10:07
Saved. See Saved Items.
This comment has already been saved in your Saved Items
good!
Carla Parrish
Carla Parrish Feb 03, 2021 8:50
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Its all a hoax ! Evil greedy lot 🤮
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email